KWF — open calls

PPP call for projects strengthening Pb-212 production/supply chain or enabling technologies for clinical application of Pb-212-based radiopharmaceuticals. Proposals must involve public-private collaboration with 40–60% industry co-funding, be submitted through KWF GMS, and align with Lead4Life governance and national TRT network. Clinical trials and full therapeutic product development are out of scope.

PPP call for projects strengthening Pb-212 production/supply chain or enabling technologies for clinical application of Pb-212-based radiopharmaceuticals. Proposals must involve public-private collaboration and be submitted through KWF GMS; projects are embedded in a national TRT innovation network. Clinical trials and full therapeutic product development are out of scope.

Add-on funding for ongoing or recently completed KWF-funded projects (incl. KWF-PPP, TTW Technology for Oncology, KWF-NWO early detection) that have reached at least TRL 3. Supports translational pathway definition, targeted development/validation, and regulatory/implementation preparation. TTO commitment letter mandatory; collaboration with TTO of applicant's research institution required.

Supports translation of KWF-funded innovations toward real-world application. Eligible only for ongoing or recently completed KWF projects (up to 1 year after completion). Covers steps such as external expertise, regulatory preparation, or business case development.

Supports late-phase (phase 2/3) international clinical trials focused on radiotherapy or surgery as core experimental interventions for rare cancers (incidence <6/100,000/year) and/or hard-to-treat cancers (5-year survival <25%). Requires partners from at least 3 of 5 funding countries; clinical-trial focus with mandatory patient involvement and quality-of-life assessment plans.

Supports late-phase (phase 2/3) international clinical trials focused on radiotherapy or surgery as core experimental interventions for rare cancers (incidence <6/100,000/year) and/or hard-to-treat cancers (5-year survival <25%). Proposals must include partners from at least 3 of the 5 funding countries and demonstrate strong rationale for international collaboration, patient involvement, and quality-of-life assessment.

International call by five European cancer charities to accelerate clinical research into local treatment strategies for rare and hard-to-treat cancers. Focuses on improving effective and accessible therapies for patients with limited treatment options.

Open to researchers with an ongoing or recently finished KWF drug research project (start ≥6 months ago, end ≤1.5 years before 1 July 2026). Funds access to clinically relevant preclinical models, technologies and expertise (e.g. NAMs, PDX, organoids, CROs) to improve translational value. Dutch institutions only; commercial partner involvement requires a letter of intent.

Supports academic-led clinical trials (Phase I–III) for new investigational medicinal products targeting cancer with unmet medical needs. Lead institute must be in the Netherlands; public participating parties must be in Europe. Patient involvement required; public-private partnerships allowed. Proposals must be in English.

Add-on funding exclusively for ongoing or recently completed KWF projects to strengthen translational relevance of oncology drug development. Supports training, implementation, and validation of advanced preclinical models; outsourcing to academic service providers or CROs is allowed.

Funds fundamental (Basic) and Credentialing cancer research addressing biological mechanisms of cancer onset, growth, and spread, as well as psychosocial mechanisms. Proposal types include Research Project, Consortium, and Unique High-Risk. Young Investigator Grants must be submitted under a separate YIG call.

Dedicated to basic research uncovering mechanisms driving cancer onset, growth, and spread. Intended for proposals within the Basic research and Credentialing phases. Aims to address knowledge gaps and identify new leads for prevention, diagnosis, and treatment.

Supports translation of KWF-funded innovations toward real-world application. Eligible only for ongoing or recently completed KWF projects (up to 1 year after completion). Covers steps such as external expertise, regulatory preparation, or business case development.

Add-on funding for ongoing or recently completed KWF-funded projects (incl. KWF-PPP, TTW Technology for Oncology, KWF-NWO early detection) that have reached at least TRL 3. Supports translational pathway definition, targeted development/validation, and regulatory/implementation preparation. TTO commitment letter mandatory; collaboration with TTO of applicant's research institution required.

PPP call within the Health~Holland-funded Lead4Life program by KWF, NRG PALLAS, FAST, and Oncode Institute. Aims to strengthen non-exclusive availability and clinical applicability of medical isotope lead-212 (Pb-212) through public-private collaboration to accelerate access to innovative cancer therapies.